咪咕体育

     咪咕体育 >> 新闻动态 >> 科研进展

科研进展

咪咕体育在TCR-T治疗HBV相关肝癌的研究中取得新进展

发表日期:2020-12-21供稿:任月飞来源:放大 缩小
  

  12月17日,国际学术期刊J Immunother Cancer在线发表了中国科学院广州生物医药与健康研究院李懿研究组的最新研究成果“In vivo therapeutic effects of affinity-improved-TCR engineered T-cells on HBV-related hepatocellular carcinoma”,该研究结果阐明了HBV抗原特异的亲和力提高的TCR-T在体外和体内研究中,其特异性和安全性与野生型WT-TCR-T相似,并且效力显著提高。该研究提出了一种治疗HBV相关HCC的新策略。 

  ZAIHUANYOUYIXINGGANYANBINGDU(HBV)XIANGGUANDEGANXIBAOAI(HCC)DEHUANZHEZHONG,BINGDUTEYIXINGXIBAODUXINGTLINBAXIBAO(CTL)WUFAXIAOCHUBIAODAHBVKANGYUANDEHCCXIBAO。YOUYUHBVXIANGGUANHCCZHONGBINGDUKANGYUANDEBIAODAKENENGJIANGDI,CONGERSHIZHONGLIUNENGGOUTAOBIMIANYIGONGJI,YINCI,KEYANRENYUANJIASHE,YUXIANGYINGDEYESHENGXINGTCRXIANGBI,HBsAgTEYIXINGDEQINHELITIGAODETCRKESHITXIBAONENGGENGYOUXIAODIBAXIANGHCC。YANJIURENYUAN,HAIJIADINGKEYILIYONGTCRZAJIAOXING(promiscuity)LAIYOUXIAOBUHUOKENENGZUAIJIYUCTLDELIAOFADEHBVBIANYI。 

  YANJIURENYUANCAIYONGDANXINGSHAIXUAN(flexi-panning)DEFANGFA,CONGSHITAIHBs370-379-SIVSPFIPLLKELONGDETCRGOUJIANDESUIJITUBIANWENKUZHONG,FENLICHUKEYUBIANTIKANGYUAN、RENBAIXIBAOKANGYUAN(HLA)-A*02:01XIANZHIDEJIUTAIHBs371-379-ILSPFLPLLJIEHEDEQINHELITIGAODETCR。YONGRENTIQIANZAIJIAOCHAFANYINGKANGYUANTAIHEHBVBIANYITAI,ZHONGLIUXIBAOHERENTIZHENGCHANGXIBAOYIJIYIZHONGYIZHIXIAOSHUGANAIMOXINGLAIYANZHENGQINHELIGAILIANGDETCRGONGCHENGTXIBAO(Ai-TCR-T)DEXIAOLIHEANQUANXING。JIEGUOXIANSHI,Ai-TCR-TXIBAOBAOLIULEXIANGGUANDEHBVKANGYUANTEYIXING,BINGSHIBIELEFANWEIGUANGFANDEHBVJIYINXINGBIANTI,JUYOUGENGGAODEMINGANXINGHEXIBAODUXING。ZAIYIZHONGYIZHIXIAOSHUGANAIMOXINGZHONG,XIBAOSHUZHUKEWANQUANXIAOCHUHCC,QIEBUHUIFUFA。CD8+ Ai-TCR-TXIBAOZAIZHONGLIUZHONGJILEIDESHENGGAOYUZHONGLIUSUOXIAOYOUGUAN。 

  GAIYANJIUHUODEGUOJIAZHONGDIANYANFAJIHUA、GUANGZHOUKEJIJIHUA、GUANGZHOUSHIZAISHENGYIXUEYUJIANKANGGUANGDONGSHENGSHIYANSHIQIANYANYANJIUJIHUA、HUXIJIBINGGUOJIAZHONGDIANSHIYANSHIZIZHUXIANGMU、HUXIXITONGJIBINGGUOJIAZHONGDIANSHIYANSHIZIZHUXIANGMUYIJIGUANGDONGSHENGXIANGMUDEZIZHU。 

  

附件:
爱游戏APP 18新利体育 中国电信爱游戏官网 九游游戏中心 爱游戏 中国电信爱游戏官网